This Article  • References  • Full text PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (7)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Philippe Berthelot, MD
CHU de Saint-Etienne Hopital de Bellevue 42055 Saint-Etienne Cedex 2, France

Claire Guglielminotti, MD; Anne Frésard, MD; Frederic Lucht, MD; Jean-Luc Perrot, MD
Saint-Etienne

Arch Dermatol. 1997;133(4):531.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Psoriasis is particularly severe and difficult to treat using conventional therapy in patients with the human immunodeficiency virus (HIV).¹ Zidovudine has already been shown to be of benefit for the treatment of psoriasis in patients with HIV,² but to our knowledge, no other antiretroviral agent has been reported to have this particular activity. We describe a 43-year-old intravenous drug abuser who since 1986 developed severe psoriasis involving 6 sites (face, umbilicus, fingers and nails, elbows, buttocks, and knees), with a global body surface area of 20%, accompanied by painful arthritis involving the wrists, fingers, and ankles. The diagnosis of psoriasis was made by a dermatologist and confirmed on a skin biopsy specimen with fungal stain. At that time the patient's HIV-positive status was discovered (enzyme-linked immunosorbent assay and Western blot technique).

Despite treatment with methotrexate (7.5 mg/wk for 1 month), which was rapidly discontinued because of patient intolerance, . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?